Globus Medical (GMED)
(Delayed Data from NYSE)
$69.98 USD
-0.42 (-0.60%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $69.98 0.00 (0.00%) 6:20 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.98 USD
-0.42 (-0.60%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $69.98 0.00 (0.00%) 6:20 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
4 Robotics Stocks to Skyrocket on Technological Advancement
by Zacks Equity Research
Robotics stocks offer great opportunities for growth investors and recent adoptions have accelerated the industry's growth rapidly.
QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test
by Zacks Equity Research
QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.
Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes
by Zacks Equity Research
Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).
Bruker Banks on Strategic Innovation Amid Coronavirus Crisis
by Zacks Equity Research
At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Globus Medical (GMED) Down 2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Globus Medical
by Zacks Equity Research
Globus Medical is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US
by Zacks Equity Research
QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.
Globus Medical Sees Strong Rebound Despite Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.
QIAGEN Launches Primer Panel for NGS of Coronavirus Genome
by Zacks Equity Research
QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.
Globus Medical (GMED) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.
Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 163.64% and 49.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Aug 5: RMD, ABC & More
by Urmimala Biswas
Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products in the second quarter.
Globus Medical (GMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical Faces Business Loss Amid Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.
New Strong Sell Stocks for May 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Globus Medical (GMED) Misses on Q1 Earnings and Revenues
by Zacks Equity Research
Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.
Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of -27.50% and -4.65%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Globus Medical (GMED) Down 28.9% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.
Globus Medical Gains From International Spine Arm, Innovation
by Zacks Equity Research
Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.
Globus Medical Stock Up on Solid '19 Preliminary Results
by Zacks Equity Research
Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.
Here's Why You Should Hold on to Globus Medical Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) on its stellar segmental performance.
Globus Medical Rides on New Product Menu, U.S. Spine Business
by Zacks Equity Research
Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.